Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participantsBin Zhou, Charles Agyemang, A. Rayner et al.|The Lancet|2024Cited by 794
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering DrugsHye Won Lee, Kamlesh Khunti, Anna Norhammar et al.|Journal of the American College of Cardiology|2018Cited by 465
Trends in incidence of total or type 2 diabetes: systematic reviewDianna J. Magliano, Jonathan E. Shaw|BMJ|2019Cited by 347
Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes CompactEdward W. Gregg, Zhaxybay Zhumadilov, James Buckley et al.|The Lancet|2023Cited by 218
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Dianna J. Magliano, Matthias Saathoff et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93